ArticleInternational journal of women's health2025
Safety of the BBIBP-CorV COVID-19 Vaccine in Relation to Adverse Clinical Outcomes in Newborns: A Prospective Cohort Study.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study is to evaluate the safety of preconception inoculation with an inactivated SARS-CoV-2 vaccine with respect to adverse birth outcomes in newborns, to elucidate the potential association between inactivated COVID-19 vaccination and birth outcomes, and to provide scientific evidence to inform future vaccine policy development. Methods: In this study, a prospective cohort design is adopted, including913 mother-infant pairs among 2243 pregnant and postpartum women who delivered between January 2023 and May 31, 2023, at You'ai Hospital and the Maternal and Child Health Hospital in Urumqi. On the basis of the number of preconception doses of an inactivated SARS-CoV-2 vaccine, Poisson regression models were used to analyse the safety of preconception vaccination in terms of adverse birth outcomes in newborns. Results: Among 913 participants, 13.8% were unvaccinated (n=126), while 1-, 2-, and 3-dose BBIBP-CorV recipients accounted for 2.4% (n=22), 17.9% (n=163), and 65.9% (n=602), respectively. Stratified analysis revealed no increased risk of adverse neonatal outcomes in any vaccinated group vs unvaccinated group (1-dose: RR 1.07 [0.67-1.71]; 2-dose: 1.02 [0.80-1.31]; 3-dose: 1.03 [0.84-1.26]). Sensitivity analysis confirmed that there were no significant differences. Conclusion: This study provides substantial evidence that prepregnancy BBIBP-CorV vaccination poses no safety concerns for neonatal outcomes. Clinically, these findings suggest that obstetricians should recommend COVID-19 vaccination during preconception counselling as a protective measure for future pregnancies. Public health implications include (1) supporting the integration of inactivated vaccines into prepregnancy health care programs to enhance immunity before gestation and (2) informing national policies to accelerate vaccine coverage among women of childbearing age, thereby reducing maternal-foetal risks in potential pandemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.